Latest News

US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy costs

The U.S. Senate health panel said on Tuesday it would vote this month on whether to subpoena Novo Nordisk to answer concerns about U.S. costs for weight-loss drugs Ozempic and Wegovy, which are far higher than those in other nations.

The Senate Committee on Health, Education, Labor, and Pensions, which is examining the drugs' expenses, said in a. statement that at its June 18 conference it will weigh a subpoena. needing Novo Nordisk Inc President Doug Langa to testify at a. July 10 hearing.

The assistance Committee has reached out time and time once again to. Novo Nordisk to request their voluntary attendance at a hearing. to talk about why they are charging Americans approximately 10 or 15 times. more for the precise very same item sold in other countries, said. Senator Bernie Sanders, who chairs the committee.

Unfortunately, despite all of our efforts, they have. repeatedly denied our requests. We look forward to their. presence at a hearing on July 10th, he stated in the declaration.

Novo Nordisk said it had worked together with the committee on. several occasions which international CEO Lars Fruergaard Jorgenson. was willing to testify.

Langa, whom the committee is voting on whether or not to. subpoena, is Novo's head of North America operations and. president of Novo Nordisk Inc, the business's U.S. subsidiary.

Based on our continued cooperation, we feel that. providing a subpoena is unneeded, the business said in a. statement.

In April, Sanders sent a letter to Langa looking for more. details on U.S. prices for the 2 drugs.

Novo responded with a May letter blaming the U.S. health. system for the high prices. It stated it retains about 60% of the. sale price for the drugs after refunds and fees paid to. intermediaries.

A 2 milligram package of Ozempic brings a market price of. $ 935.77 in the U.S., while Wegovy has a sale price of $1,349.02. per plan, according to the drugmaker's site.

(source: Reuters)